U.S. pharma giant copyright scrapped two experimental weight loss products previous 12 months—a when-each day tablet, lotiglipron, as a consequence of elevated liver enzymes as well as a twice-everyday tablet, danuglipron, resulting from robust side effects—but CEO Albert Bourla has reported the company is decided to “Participate in and acqui